ZBTB2

Summary

ZBTB2 (zinc finger and BTB domain containing 2, HGNC:20868) is a protein-coding gene on chromosome 6q25.1, encoding Zinc finger and BTB domain-containing protein 2 (Q8N680). May be involved in transcriptional regulation.

Enables DNA-binding transcription repressor activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and identical protein binding activity. Involved in negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be active in nucleoplasm.

Source: NCBI Gene 57621 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 51 total
• Druggable target: yes
• MANE Select transcript: NM_020861

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20868
Approved symbol	ZBTB2
Name	zinc finger and BTB domain containing 2
Location	6q25.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1483, ZNF437, bA351K16.2
Ensembl gene	ENSG00000181472
Ensembl biotype	protein_coding
OMIM	616595
Entrez	57621

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000325144, ENST00000869305, ENST00000869306, ENST00000869307, ENST00000869308, ENST00000869309, ENST00000869310, ENST00000936201, ENST00000936202, ENST00000936203

RefSeq mRNA: 1 — MANE Select: NM_020861 NM_020861

CCDS: CCDS5231

Canonical transcript exons

ENST00000325144 — 3 exons

Exon	Start	End
ENSE00001247407	151391420	151391559
ENSE00001247421	151364115	151366892
ENSE00001444138	151373465	151373649

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 97.47.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.3303 / max 150.5887, expressed in 1773 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
76183	6.4234	1644
76184	1.3886	914
76186	1.3114	930
76185	0.7395	479
76180	0.5501	196
76188	0.4898	257
76187	0.4276	206

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.47	gold quality
oocyte	CL:0000023	93.24	gold quality
epithelial cell of pancreas	CL:0000083	91.24	gold quality
sperm	CL:0000019	86.08	gold quality
granulocyte	CL:0000094	84.43	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.06	gold quality
leukocyte	CL:0000738	83.99	gold quality
monocyte	CL:0000576	83.73	gold quality
tibialis anterior	UBERON:0001385	82.02	gold quality
lymph node	UBERON:0000029	82.01	gold quality
smooth muscle tissue	UBERON:0001135	81.83	gold quality
ganglionic eminence	UBERON:0004023	81.80	gold quality
cortical plate	UBERON:0005343	81.69	gold quality
hindlimb stylopod muscle	UBERON:0004252	81.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.33	gold quality
thyroid gland	UBERON:0002046	81.12	gold quality
gastrocnemius	UBERON:0001388	81.10	gold quality
stromal cell of endometrium	CL:0002255	81.04	gold quality
deltoid	UBERON:0001476	80.88	silver quality
gingival epithelium	UBERON:0001949	80.83	silver quality
popliteal artery	UBERON:0002250	80.76	gold quality
tibial artery	UBERON:0007610	80.76	gold quality
ventricular zone	UBERON:0003053	80.75	gold quality
muscle of leg	UBERON:0001383	80.74	gold quality
rectum	UBERON:0001052	80.44	gold quality
left lobe of thyroid gland	UBERON:0001120	80.37	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.31	gold quality
right lobe of thyroid gland	UBERON:0001119	80.00	gold quality
gingiva	UBERON:0001828	79.98	silver quality
ileal mucosa	UBERON:0000331	79.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.04

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

4 targets.

Target	Regulation
ARF1	Repression
CDKN1A	Repression
MDM2	Activation
TP53	Repression

miRNA regulators (miRDB)

171 targeting ZBTB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-3658	99.96	73.87	4379

Literature-anchored findings (GeneRIF, showing 13)

• ZBTB2 is a potential proto-oncogenic master control gene of the p53 pathway and, in particular, is a potent transcription repressor of the cell cycle arrest gene p21 by inhibiting p53 and Sp1 (PMID:19380588)
• ZBTB2 being considered as a multifunctional cell proliferation activator, notably through p21 repression, this work points out new epigenetic processes potentially involved in carcinogenesis. (PMID:24607898)
• ZBTB2 may increase cell proliferation by reprogramming glucose metabolic pathways to favor glycolysis by upregulating PDK4 expression via repression of RelA/p65 expression (PMID:25609694)
• long noncoding RNA CALML3-AS1 promotes tumorigenesis of bladder cancer via regulating ZBTB2 by suppression of microRNA-4316 (PMID:30177388)
• MicroRNA-488-3p inhibits proliferation and induces apoptosis by targeting ZBTB2 in esophageal squamous cell carcinoma. (PMID:31243806)
• MiR-4282 inhibits tumor progression through down-regulation of ZBTB2 by targeting LIN28B in oral squamous cell carcinoma. (PMID:31970774)
• OIP5-AS1 promotes the progression of gastric cancer cells via the miR-153-3p/ZBTB2 axis. (PMID:32196594)
• ZBTB2 protein is a new partner of the Nucleosome Remodeling and Deacetylase (NuRD) complex. (PMID:33301849)
• ZBTB2 links p53 deficiency to HIF-1-mediated hypoxia signaling to promote cancer aggressiveness. (PMID:36341521)
• ZBTB2 is Recruited to a Specific Subset of HIF-1 Target Loci to Facilitate Full Gene Expression Under Hypoxia. (PMID:37257772)
• The novel circ_0004674/miR-139-5p/ZBTB2 regulatory cascade inhibits the development of oral squamous cell carcinoma. (PMID:38665011)
• ZBTB7A forms a heterodimer with ZBTB2 and inhibits ZBTB2 homodimerization required for full activation of HIF-1. (PMID:39197198)
• APC and ZBTB2 May Mediate M2 Macrophage Infiltration to Promote the Development of Renal Fibrosis: A Bioinformatics Analysis. (PMID:39328595)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	znfl2a	ENSDARG00000008333
danio_rerio	zbtb2b	ENSDARG00000028086
danio_rerio	zbtb2a	ENSDARG00000044038
mus_musculus	Zbtb2	ENSMUSG00000075327
rattus_norvegicus	Zbtb2	ENSRNOG00000019544

Protein

Protein identifiers

Zinc finger and BTB domain-containing protein 2 — Q8N680 (reviewed: Q8N680)

All UniProt accessions (1): Q8N680

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

RefSeq proteins (1): NP_065912* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF00651

UniProt features (17 total): cross-link 6, zinc finger region 4, compositionally biased region 2, chain 1, domain 1, sequence conflict 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N680-F1	57.51	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 147, 154, 362, 465, 505, 506, 341

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 196 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, TAATAAT_MIR126, CTATGCA_MIR153, WEI_MYCN_TARGETS_WITH_E_BOX, chr6q25, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_CYTOKINE_PRODUCTION, DODD_NASOPHARYNGEAL_CARCINOMA_UP, AACTTT_UNKNOWN, TGAGATT_MIR216, TAATGTG_MIR323, SOX5_01, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, ZHENG_BOUND_BY_FOXP3, WGTTNNNNNAAA_UNKNOWN

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of cytokine production (GO:0001817), regulation of immune system process (GO:0002682)

GO Molecular Function (8): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleoplasm (GO:0005654), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cytokine production	1
regulation of gene expression	1
regulation of multicellular organismal process	1
immune system process	1
regulation of biological process	1
cis-regulatory region sequence-specific DNA binding	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transition metal ion binding	1
protein binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
nuclear lumen	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1496 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZBTB2	RMND1	Q9NWS8	655
ZBTB2	DCPH1	Q9H993	633
ZBTB2	CCDC170	Q8IYT3	584
ZBTB2	UBN2	Q6ZU65	566
ZBTB2	CABIN1	Q9Y6J0	553
ZBTB2	ZNF639	Q9UID6	487
ZBTB2	SP1	P08047	484
ZBTB2	MTHFD1L	Q6UB35	451
ZBTB2	KLHL15	Q96M94	447
ZBTB2	PLEKHG1	Q9ULL1	447
ZBTB2	PPP1R14C	Q8TAE6	406
ZBTB2	TMEM33	P57088	396
ZBTB2	IER5L	Q5T953	383
ZBTB2	ZBTB7A	O95365	372
ZBTB2	AKAP12	Q02952	367

IntAct

158 interactions, top by confidence:

A	B	Type	Score
HDAC2	KDM1A	psi-mi:“MI:0914”(association)	0.890
PRDM14	CBFA2T2	psi-mi:“MI:0914”(association)	0.860
HDAC1	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
RBBP7	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
HDAC1	TNRC18	psi-mi:“MI:0914”(association)	0.790
RBBP4	CDK2AP1	psi-mi:“MI:0914”(association)	0.790
P4HB	P4HA2	psi-mi:“MI:0914”(association)	0.740
HDAC1	ZNF609	psi-mi:“MI:0914”(association)	0.730
RBBP7	HAT1	psi-mi:“MI:0914”(association)	0.730
ZBTB2	ZNF639	psi-mi:“MI:0915”(physical association)	0.670
ZBTB2	RASSF8	psi-mi:“MI:0915”(physical association)	0.670
ZBTB25	ZBTB2	psi-mi:“MI:0915”(physical association)	0.670
ZBTB2	ZBTB25	psi-mi:“MI:0914”(association)	0.670
ZNF219	CDK2AP1	psi-mi:“MI:0914”(association)	0.640
CARNMT1	NUP42	psi-mi:“MI:0914”(association)	0.640
SPOP	JUN	psi-mi:“MI:0914”(association)	0.600
ZBTB2	SPOP	psi-mi:“MI:0915”(physical association)	0.600
ZBTB2	SPOP	psi-mi:“MI:2364”(proximity)	0.600
SPOP	ZBTB2	psi-mi:“MI:2364”(proximity)	0.600
ZBTB2	SP1	psi-mi:“MI:0915”(physical association)	0.580
SP1	ZBTB2	psi-mi:“MI:0915”(physical association)	0.580
SUMO1	ZBTB2	psi-mi:“MI:0915”(physical association)	0.560
ZBTB2	ZBTB18	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (496): ZBTB2 (Reconstituted Complex), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), ZBTB2 (Affinity Capture-MS), SP1 (Affinity Capture-Western), ZBTB2 (Affinity Capture-Western), SP1 (Reconstituted Complex)

ESM2 similar proteins: A0JN76, A1L2U9, B1WAZ8, B1WBU4, O15060, O35260, O43298, O93567, P14404, P41182, P41183, Q05516, Q0IH98, Q0IJ29, Q0P4X6, Q0V8G8, Q0VCJ6, Q15916, Q1L8W0, Q3B725, Q3SWU4, Q5TC79, Q5ZM39, Q6NRM8, Q6P882, Q6YND2, Q7TQG0, Q7TSZ8, Q7ZWZ4, Q801P1, Q80X44, Q86UZ6, Q8BID6, Q8CII0, Q8K088, Q8K0L9, Q8N680, Q8NAP8, Q8NCN2, Q8NCP5

Diamond homologs: A0JN76, A1L2U9, A1YEX3, A1YPR0, A2AAX3, B1WAZ8, B1WBS3, B1WBU4, B2RXF5, D3ZA50, O14867, O15062, O15156, O15209, O43167, O43298, O43829, O88282, O88939, O93567, O95365, P24278, P41182, P41183, P52739, P97302, P97303, Q08376, Q0IH98, Q0IJ29, Q0P4X6, Q0VCJ6, Q13105, Q14526, Q1H9T6, Q1L8W0, Q2T9Z7, Q3B725, Q3B7N9, Q3SWU4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 90 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	6	35.1×	2e-06
Regulation of PTEN gene transcription	8	22.0×	8e-07
RNA Polymerase I Transcription Initiation	6	20.7×	5e-05
NuRD complex assembly	9	19.5×	5e-07
Maturation of DENV proteins	6	19.5×	6e-05
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	8	18.0×	2e-06
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	6	13.5×	4e-04
Potential therapeutics for SARS	7	12.3×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
regulation of stem cell differentiation	5	45.1×	1e-05
positive regulation of stem cell population maintenance	5	20.2×	4e-04
negative regulation of transforming growth factor beta receptor signaling pathway	6	12.3×	8e-04
negative regulation of cell migration	6	7.9×	5e-03
chromatin remodeling	8	6.9×	2e-03
DNA damage response	8	5.0×	8e-03
negative regulation of cell population proliferation	9	4.5×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

674 predictions. Top by Δscore:

Variant	Effect	Δscore
6:151366889:CTCA:C	acceptor_gain	1.0000
6:151366891:CA:C	acceptor_gain	1.0000
6:151366892:AC:A	acceptor_loss	1.0000
6:151366893:C:CC	acceptor_gain	1.0000
6:151366893:CTGAA:C	acceptor_loss	1.0000
6:151391415:CTTA:C	donor_loss	1.0000
6:151391416:TTACC:T	donor_loss	1.0000
6:151391417:TACCT:T	donor_loss	1.0000
6:151391418:A:AC	donor_gain	1.0000
6:151391418:A:T	donor_loss	1.0000
6:151391419:C:CC	donor_gain	1.0000
6:151391419:C:CG	donor_loss	1.0000
6:151391419:CCTGT:C	donor_gain	1.0000
6:151366888:ACTCA:A	acceptor_gain	0.9900
6:151366889:CTCAC:C	acceptor_gain	0.9900
6:151366890:TCA:T	acceptor_gain	0.9900
6:151366890:TCAC:T	acceptor_gain	0.9900
6:151366891:CAC:C	acceptor_gain	0.9900
6:151366894:T:A	acceptor_loss	0.9900
6:151366903:C:CT	acceptor_gain	0.9900
6:151366904:A:T	acceptor_gain	0.9900
6:151373528:G:A	donor_gain	0.9900
6:151388935:C:CT	donor_gain	0.9900
6:151388936:T:TT	donor_gain	0.9900
6:151391418:AC:A	donor_gain	0.9900
6:151391419:CC:C	donor_gain	0.9900
6:151391419:CCT:C	donor_gain	0.9900
6:151366737:T:TA	donor_gain	0.9800
6:151366906:G:C	acceptor_gain	0.9800
6:151391419:CCTG:C	donor_gain	0.9800

AlphaMissense

3401 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:151365718:A:G	C450R	1.000
6:151365842:G:C	H408Q	1.000
6:151365842:G:T	H408Q	1.000
6:151365843:T:C	H408R	1.000
6:151365844:G:C	H408D	1.000
6:151365844:G:T	H408N	1.000
6:151365863:C:A	R401S	1.000
6:151365863:C:G	R401S	1.000
6:151365864:C:A	R401M	1.000
6:151365864:C:G	R401T	1.000
6:151365869:A:C	F399L	1.000
6:151365869:A:T	F399L	1.000
6:151365870:A:C	F399C	1.000
6:151365870:A:G	F399S	1.000
6:151365871:A:G	F399L	1.000
6:151365881:A:C	C395W	1.000
6:151365882:C:T	C395Y	1.000
6:151365883:A:G	C395R	1.000
6:151365890:G:C	C392W	1.000
6:151365891:C:G	C392S	1.000
6:151365892:A:G	C392R	1.000
6:151365892:A:T	C392S	1.000
6:151365896:G:C	F390L	1.000
6:151365896:G:T	F390L	1.000
6:151365898:A:G	F390L	1.000
6:151365911:G:C	H385Q	1.000
6:151365911:G:T	H385Q	1.000
6:151365912:T:A	H385L	1.000
6:151365912:T:C	H385R	1.000
6:151365912:T:G	H385P	1.000

dbSNP variants (sampled 300 via entrez): RS1000025207 (6:151389981 C>T), RS1000099038 (6:151384324 C>G), RS1000120347 (6:151390926 C>T), RS1000165155 (6:151382807 G>A), RS1000193493 (6:151375061 G>A), RS1000224481 (6:151375366 A>C,T), RS1000269012 (6:151366160 G>A), RS1000401892 (6:151369311 G>A), RS1000487330 (6:151373395 T>C), RS1000503119 (6:151380178 C>T), RS1000540666 (6:151373868 A>C), RS1000704427 (6:151373664 ATTTTAT>A), RS1000747546 (6:151368352 T>C), RS1000904588 (6:151393462 CA>C), RS1000994873 (6:151385807 C>A,T)

Disease associations

OMIM: gene MIM:616595 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001063_1	Chronic myeloid leukemia	2.000000e-06
GCST010002_338	Refractive error	5.000000e-20
GCST90000025_133	Appendicular lean mass	3.000000e-17
GCST90002393_581	Monocyte count	8.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004980	appendicular lean mass
EFO:0005091	monocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5069373 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	4
Formaldehyde	decreases expression	2
Silver	increases expression	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	affects expression, decreases expression	2
aristolochic acid I	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	decreases expression	1
beta-lapachone	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-phenylbutyric acid	decreases expression	1
pentabromodiphenyl ether	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Caffeine	affects phosphorylation	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	increases expression	1
Hydrogen Peroxide	affects expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Phenobarbital	affects expression	1
Quercetin	decreases expression	1
Rotenone	decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5059506	Binding	Proteomics fold change data (SUDHL4 cells, 1h)	Data for DCP probe CCT369260

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.